Envy Medical, Inc.

Escape Therapeutics, Inc.

Leland Stanford Junior University

Reliant Technologies, Inc.

Agex Therapeutics, Inc.

Basil M Hantash

Kenneth B Karasiuk

N Brendon Boone, Iii

Steven Edward Wojcik

Kin F Chan

Anan Abu Ubeid

Brendon N Boone

George Frangineas, Jr

Leonard C DeBenedictis

Ying Wang

G Scott Herron

Vikramaditya P Bedi

Isolated populations of mesenchymal stem cells (MSCs) are provided, including mammalian mesenchymal stem cells (MSCs) characterized by the lack of CD54 (CD54) or low cell-surface CD54 (CD54). Methods of in vitro cell differentiation and methods of treatment using said isolated populations are also provided.

Enhanced differentiation of mesenchymal stem cells

Tyrosine inhibitors having immunosuppressive activity in human neonatal keratinocyte progenitors are described. Particular embodiments feature the immunosuppressive effects of a decapeptide and/or oxyresveratrol, as measured by two different methods: blockade of stimulated cell growth, and inhibition of cytotoxic killing.

Tyrosine inhibitors with immunosuppressive activity in human neonatal keratinocyte progenitors

Compositions of HLA-G+ MSC and methods of using them, including methods of transplanting compositions of HLA-G+ MSC into human recipients, are provided. Also provided are methods of preparing compositions of HLA-G+ MSC, including by treatment with DNA methylation inhibitors.

Mesenchymal stem cells with enhanced immunosuppressive capability

Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.

HLA G-modified cells and methods

An abrasive tip is used to exfoliate skin and tissue through abrasive materials integrated in the tip. The tip also delivers fluid to the skin and vacuums the fluid and abraded tissue during treatment. Treated skin will look younger and healthier in appearance. In an implementation, the tip is replaceable and disposable.

Microdermabrasion treatment heads

Compositions of HLA-GMSC and methods of using them, including methods of transplanting compositions of HLA-GMSC into human recipients, are provided. Also provided are methods of preparing compositions of HLA-GMSC, including by treatment with DNA methylation inhibitors.

A distance between a surface of a treatment head and tip opening of a skin treatment hand piece is adjustable. In an implementation, the distance is adjusted by moving the tip opening relative to the treatment head surface. Different distances may be used to treat different skin types, problems, and conditions. In an implementation, the hand piece includes a fluid delivery and a vacuum or suction mechanism to provide various therapeutic benefits to the skin.

Skin treatment system with adjustable height wand

A microdermabrasion system offers a combination of other skin therapies in conjunction with microdermabrasion. In an implementation, the system applies light therapy, photodynamic therapy, radio frequency and microwave energy therapy, massage therapy, or combinations of these while exfoliating the skin.

Microdermabrasion system with combination skin therapies

A microdermabrasion system upgrade kit includes a plurality of couplers from which a user may choose one or more couplers in order to connect the upgrade kit to a vacuum source of an existing microdermabrasion system. In an implementation, the upgrade kit includes a power socket that the user can plug the vacuum source into.

Microdermabrasion system upgrade kit

Disclosed herein are genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.

Peptides that increase melanin synthesis are provided. These peptides include pentapeptides YSSWY (SEQ ID NO: 1), YRSRK (SEQ ID NO: 2), and their variants. The peptides may activate the enzymatic activity of tyrosinase to increase melanin synthesis. The pharmaceutical, cosmetic, and other compositions including the peptides are also provided. The methods of increasing melanin production in epidermis of a subject are provided where the methods include administering compositions comprising an amount of one or more peptides effective to increase the melanin production. The methods also include treating vitiligo or other hypopigmentation disorders with compositions including one or more peptides.

Growing community of inventors

East Palo Alto, CA, United States of America

Basil M Hantash